Anavex Life Sciences CorpNASDAQ:AVXL
- LAST PRICE4.0600
- TODAY'S CHANGE (%)-0.0800 (-1.9324%)
- Bid / Lots4.0000/ 1
- Ask / Lots4.4200/ 30
- Open / Previous Close4.1700 / 4.1400
- Day Range
- 52 Week Range
- Volume3,048,229
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AVXL |
|---|---|---|
| 09:32 ET | 8008 | 4.13 |
| 09:34 ET | 2750 | 4.1123 |
| 09:36 ET | 9318 | 4.15 |
| 09:38 ET | 3807 | 4.13 |
| 09:39 ET | 2111 | 4.16 |
| 09:41 ET | 2962 | 4.18 |
| 09:43 ET | 4340 | 4.197 |
| 09:45 ET | 874 | 4.19 |
| 09:48 ET | 2336 | 4.195 |
| 09:50 ET | 2112 | 4.17 |
| 09:52 ET | 3758 | 4.17 |
| 09:54 ET | 15466 | 4.145 |
| 09:56 ET | 6812 | 4.145 |
| 09:57 ET | 1046 | 4.145 |
| 09:59 ET | 11272 | 4.19 |
| 10:01 ET | 8359 | 4.1903 |
| 10:03 ET | 4866 | 4.195 |
| 10:06 ET | 1900 | 4.195 |
| 10:08 ET | 1127 | 4.19 |
| 10:10 ET | 8893 | 4.145 |
| 10:12 ET | 748 | 4.1384 |
| 10:14 ET | 1600 | 4.1075 |
| 10:15 ET | 2717 | 4.105 |
| 10:17 ET | 2870 | 4.125 |
| 10:19 ET | 1961 | 4.135 |
| 10:21 ET | 1893 | 4.15 |
| 10:24 ET | 1764 | 4.17 |
| 10:26 ET | 6227 | 4.15 |
| 10:28 ET | 469 | 4.14 |
| 10:30 ET | 2480 | 4.12 |
| 10:32 ET | 700 | 4.105 |
| 10:33 ET | 1502 | 4.12 |
| 10:37 ET | 311 | 4.105 |
| 10:39 ET | 1416 | 4.115 |
| 10:42 ET | 100 | 4.115 |
| 10:44 ET | 1242 | 4.1 |
| 10:46 ET | 4533 | 4.1 |
| 10:48 ET | 5503 | 4.0883 |
| 10:51 ET | 2413 | 4.0885 |
| 10:53 ET | 400 | 4.085 |
| 10:55 ET | 8395 | 4.11 |
| 10:57 ET | 1156 | 4.105 |
| 11:02 ET | 3811 | 4.12 |
| 11:04 ET | 802 | 4.1 |
| 11:06 ET | 1163 | 4.1 |
| 11:08 ET | 210 | 4.1 |
| 11:09 ET | 400 | 4.105 |
| 11:11 ET | 1801 | 4.115 |
| 11:13 ET | 5900 | 4.105 |
| 11:15 ET | 1966 | 4.095 |
| 11:20 ET | 500 | 4.085 |
| 11:22 ET | 200 | 4.07 |
| 11:24 ET | 940 | 4.0708 |
| 11:26 ET | 392 | 4.075 |
| 11:27 ET | 300 | 4.07 |
| 11:29 ET | 2288 | 4.065 |
| 11:31 ET | 100 | 4.065 |
| 11:33 ET | 4018 | 4.055 |
| 11:36 ET | 3445 | 4.065 |
| 11:38 ET | 2410 | 4.05 |
| 11:40 ET | 2787 | 4.0599 |
| 11:42 ET | 5381 | 4.08 |
| 11:44 ET | 100 | 4.075 |
| 11:45 ET | 700 | 4.075 |
| 11:47 ET | 991 | 4.07 |
| 11:49 ET | 1518 | 4.07 |
| 11:51 ET | 200 | 4.07 |
| 11:54 ET | 2200 | 4.065 |
| 11:56 ET | 1125 | 4.0636 |
| 11:58 ET | 2136 | 4.0658 |
| 12:00 ET | 2837 | 4.06 |
| 12:02 ET | 1884 | 4.05 |
| 12:05 ET | 1768 | 4.05 |
| 12:07 ET | 795 | 4.045 |
| 12:09 ET | 1558 | 4.0475 |
| 12:12 ET | 100 | 4.055 |
| 12:14 ET | 1857 | 4.035 |
| 12:16 ET | 4853 | 4.055 |
| 12:18 ET | 100 | 4.055 |
| 12:20 ET | 513 | 4.055 |
| 12:21 ET | 3484 | 4.045 |
| 12:23 ET | 1461 | 4.045 |
| 12:25 ET | 1666 | 4.06 |
| 12:30 ET | 111 | 4.055 |
| 12:32 ET | 1332 | 4.045 |
| 12:34 ET | 1500 | 4.045 |
| 12:36 ET | 1663 | 4.05 |
| 12:38 ET | 5113 | 4.0674 |
| 12:39 ET | 665 | 4.0797 |
| 12:41 ET | 100 | 4.08 |
| 12:43 ET | 2933 | 4.07 |
| 12:45 ET | 450 | 4.065 |
| 12:48 ET | 501 | 4.06 |
| 12:52 ET | 1518 | 4.06 |
| 12:54 ET | 600 | 4.0603 |
| 12:56 ET | 200 | 4.07 |
| 12:59 ET | 300 | 4.065 |
| 01:01 ET | 400 | 4.065 |
| 01:03 ET | 8061 | 4.1 |
| 01:06 ET | 3212 | 4.075 |
| 01:08 ET | 100 | 4.075 |
| 01:10 ET | 998 | 4.065 |
| 01:12 ET | 500 | 4.065 |
| 01:14 ET | 670 | 4.0609 |
| 01:15 ET | 1500 | 4.065 |
| 01:17 ET | 1941 | 4.055 |
| 01:19 ET | 300 | 4.055 |
| 01:21 ET | 200 | 4.055 |
| 01:24 ET | 4924 | 4.09 |
| 01:26 ET | 200 | 4.1 |
| 01:28 ET | 680 | 4.11 |
| 01:30 ET | 4385 | 4.11 |
| 01:32 ET | 1671 | 4.11 |
| 01:33 ET | 1750 | 4.1 |
| 01:35 ET | 3728 | 4.1 |
| 01:37 ET | 3425 | 4.0946 |
| 01:39 ET | 780 | 4.09 |
| 01:42 ET | 728 | 4.095 |
| 01:44 ET | 2965 | 4.095 |
| 01:46 ET | 1250 | 4.095 |
| 01:48 ET | 5888 | 4.1 |
| 01:50 ET | 1040 | 4.12 |
| 01:51 ET | 719 | 4.1199 |
| 01:53 ET | 2689 | 4.12 |
| 01:55 ET | 1847 | 4.115 |
| 01:57 ET | 894 | 4.1191 |
| 02:00 ET | 2748 | 4.115 |
| 02:02 ET | 3565 | 4.1068 |
| 02:04 ET | 2399 | 4.105 |
| 02:06 ET | 465 | 4.095 |
| 02:08 ET | 12840 | 4.115 |
| 02:09 ET | 1200 | 4.125 |
| 02:11 ET | 200 | 4.13 |
| 02:13 ET | 28797 | 4.15 |
| 02:15 ET | 500 | 4.15 |
| 02:18 ET | 4206 | 4.155 |
| 02:20 ET | 311 | 4.155 |
| 02:22 ET | 300 | 4.155 |
| 02:24 ET | 4536 | 4.145 |
| 02:26 ET | 3043 | 4.15 |
| 02:27 ET | 1608 | 4.14 |
| 02:29 ET | 100 | 4.135 |
| 02:31 ET | 3720 | 4.135 |
| 02:38 ET | 1366 | 4.13 |
| 02:40 ET | 1191 | 4.115 |
| 02:42 ET | 3884 | 4.125 |
| 02:44 ET | 670 | 4.125 |
| 02:45 ET | 475 | 4.125 |
| 02:47 ET | 300 | 4.125 |
| 02:49 ET | 1762 | 4.115 |
| 02:51 ET | 100 | 4.115 |
| 02:54 ET | 2100 | 4.105 |
| 02:56 ET | 3855 | 4.11 |
| 03:02 ET | 8783 | 4.1145 |
| 03:03 ET | 9881 | 4.105 |
| 03:05 ET | 5800 | 4.1015 |
| 03:07 ET | 6517 | 4.12 |
| 03:09 ET | 711 | 4.135 |
| 03:12 ET | 1250 | 4.135 |
| 03:14 ET | 1978 | 4.135 |
| 03:16 ET | 200 | 4.14 |
| 03:18 ET | 3400 | 4.135 |
| 03:20 ET | 5215 | 4.1242 |
| 03:21 ET | 783 | 4.1155 |
| 03:23 ET | 6922 | 4.13 |
| 03:25 ET | 300 | 4.125 |
| 03:27 ET | 300 | 4.13 |
| 03:30 ET | 2553 | 4.115 |
| 03:32 ET | 1226 | 4.105 |
| 03:34 ET | 626 | 4.11 |
| 03:36 ET | 2188 | 4.1056 |
| 03:38 ET | 2548 | 4.12 |
| 03:39 ET | 400 | 4.12 |
| 03:41 ET | 2380 | 4.13 |
| 03:43 ET | 783 | 4.13 |
| 03:45 ET | 5117 | 4.13 |
| 03:48 ET | 1100 | 4.1297 |
| 03:50 ET | 5017 | 4.13 |
| 03:52 ET | 28366 | 4.095 |
| 03:54 ET | 6340 | 4.1 |
| 03:56 ET | 17815 | 4.06 |
| 03:57 ET | 37553 | 4.055 |
| 03:59 ET | 1876133 | 4.06 |
May 22, 2024
Press Release: Anavex Life Sciences Announces Expansion of Leadership Team, from 7:30AM ET on Wednesday May 22, 2024 by Dow Jones
7:30AM ET on Wednesday May 22, 2024 by Dow JonesAnavex Life Sciences Announces Expansion of Leadership Team, from 7:30AM ET on Wednesday May 22, 2024 by Dow Jones
7:30AM ET on Wednesday May 22, 2024 by Dow Jones
May 21, 2024
Lifshitz Law PLLC Announces Investigations of Anavex Life Sciences Corporation (NASDAQ:AVXL), Innoviz Technologies Ltd. (NASDAQ:INVZ), agilon health, inc. (NYSE:AGL), and The Chemours Company (NYSE:CC), from 7:47AM ET on Tuesday May 21, 2024 by Dow Jones
7:47AM ET on Tuesday May 21, 2024 by Dow Jones
May 14, 2024
AVXL ALERT: Bragar Eagel & Squire, P.C. is Investigating Anavex Life Sciences Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm, from 9:00PM ET on Tuesday May 14, 2024 by Dow Jones
9:00PM ET on Tuesday May 14, 2024 by Dow JonesAnavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ, from 7:30AM ET on Tuesday May 14, 2024 by Dow Jones
7:30AM ET on Tuesday May 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Anavex Life Sciences Corp | 343.6M | -8.2x | --- |
Nautilus Biotechnology Inc | 343.2M | -5.1x | --- |
Ventyx Biosciences Inc | 337.0M | -1.5x | --- |
Zura Bio Ltd | 334.3M | -3.2x | --- |
Tourmaline Bio Inc | 353.2M | -2.6x | --- |
Tenaya Therapeutics Inc | 330.6M | -2.6x | --- |
Company Information
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.
Contact Information
- Headquarters
- 630 5Th Avenue, 20Th FloorNEW YORK, NY, United States 10111
- Phone
- 800-689-3939
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer, Company Secretary
- Christopher Missling
- Principal Financial Officer, Treasurer
- Sandra Boenisch
- Lead Independent Director
- Claus van der Velden
- Independent Director
- Peter Donhauser
- Independent Director
- Jiong Ma
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $343.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 84.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.67 |
EPS | $-0.50 |
Book Value | $1.73 |
P/E Ratio | -8.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
